
Celltrion opens new UK headquarters in Uxbridge to drive long-term growth
Ella Day | June 19, 2025 | News story | Research and Development | Corporate, Pharmacy, biosimilar medicines, celltrion
Celltrion, focused on the development of biosimilar medicines, has officially opened its new UK headquarters in the Charter Building, Uxbridge, indicating its ongoing commitment to the UK healthcare market. The new office will be used as a central hub for UK operations and aligns the company with other leading pharmaceutical and biotech firms that have established a presence in the region.
The ribbon-cutting ceremony was attended by Hyoung-Ki Kim, CEO and vice chairman of Celltrion, Rosalind Campion, director of the office for life sciences, UK, and Mark Samuels, chief executive of Medicines UK and the British Biosimilars Association.
“The opening of our new UK office marks a pivotal milestone in Celltrion UK history,” said Kim. “We are here for the long term and are invested in the future of biosimilars in the UK. We look forward to continued collaboration with local institutions and regulatory bodies to ensure sustainable access to high-quality biologic treatments.”
Campion noted the relevance of biosimilars to UK healthcare priorities: “With the NHS prescribing 80% generic by volume, the next frontier is biosimilars. This is a pivotal time for the sector.”
Celltrion UK anticipates further growth as it prepares to launch new treatments across allergy, endocrinology, ophthalmology and immunology.
“This investment supports British jobs and essential medicines for the NHS,” added Samuels.
The move reflects Celltrion’s long-term strategy to strengthen its role as a key player in the UK life sciences ecosystem and the global biosimilars market.
Ella Day
19/6/25

This article featured in: July 2025 – The Pharmafile Brief
Related Content

Celltrion launches Humira biosimilar in US
South Korean biopharmaceutical company Celltrion has announced that its US branch – Celltrion USA – …

Experimental COVID antibody treatment successful in trials
Celltrion has announced positive top-line data for its experimental antibody COVID-19 treatment, with Phase III …

Celltrion’s COVID-19 treatment shows promise against South African variant
Celltrion’s regdanvimab treatment for COVID-19 has shown itself to be effective against the South African …






